Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 3
1956 1
1957 1
1958 3
1959 2
1960 2
1962 5
1963 4
1964 3
1965 4
1966 4
1967 10
1968 7
1969 4
1970 6
1971 5
1972 13
1973 6
1974 12
1975 15
1976 8
1977 13
1978 16
1979 25
1980 28
1981 30
1982 43
1983 50
1984 55
1985 44
1986 67
1987 61
1988 69
1989 76
1990 64
1991 62
1992 78
1993 65
1994 62
1995 83
1996 89
1997 76
1998 70
1999 96
2000 88
2001 104
2002 83
2003 93
2004 108
2005 116
2006 127
2007 126
2008 129
2009 141
2010 127
2011 172
2012 144
2013 141
2014 157
2015 127
2016 133
2017 154
2018 151
2019 162
2020 181
2021 225
2022 209
2023 176
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

4,427 results

Results by year

Filters applied: . Clear all
Page 1
Practical guide for safe sedation.
Hara T, Ozawa A, Shibutani K, Tsujino K, Miyauchi Y, Kawano T, Ito K, Sakai H, Yokota M; Working Group for the Preparation of Practical Guidelines for Safe Sedation, Safety Committee of the Japanese Society of Anesthesiologists. Hara T, et al. Among authors: sakai h. J Anesth. 2023 Jun;37(3):340-356. doi: 10.1007/s00540-023-03177-5. Epub 2023 Mar 13. J Anesth. 2023. PMID: 36912977 Review.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. Paz-Ares LG, et al. Among authors: sakai h. J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12. J Thorac Oncol. 2022. PMID: 34648948 Free article. Clinical Trial.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. Paz-Ares L, et al. Among authors: sakai h. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476593 Clinical Trial.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Reck M, et al. Among authors: sakai h. ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1. ESMO Open. 2021. PMID: 34607285 Free PMC article. Clinical Trial.
Chronic neutrophilic leukemia preceded by myelodysplastic syndromes.
Baba Y, Nakamaki T, Sakai H, Fukuchi K, Kabasawa N, Hattori N, Harada H. Baba Y, et al. Among authors: sakai h. Int J Hematol. 2023 Nov;118(5):636-641. doi: 10.1007/s12185-023-03636-5. Epub 2023 Jul 13. Int J Hematol. 2023. PMID: 37439996
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK. Le X, et al. Among authors: sakai h. Clin Cancer Res. 2022 Mar 15;28(6):1117-1126. doi: 10.1158/1078-0432.CCR-21-2733. Clin Cancer Res. 2022. PMID: 34789481 Free PMC article. Clinical Trial.
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, Tanizaki J, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K. Suzuki S, et al. Among authors: sakai h. Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7. Clin Cancer Res. 2021. PMID: 34365406
4,427 results